Compare Stocks: EPIX, CRVO, ADXS, and PYRGF

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXS Ayala Pharmaceuticals	$0.60	$0.60	$0.00 ▼ $0.80	$35.79M	1.75	15,632 shs	N/A
CRVO CervoMed	$2.43 -4.7%	$2.70	$2.13 ▼ $10.00	$36.74M	-0.64	166,180 shs	179,670 shs
EPIX ESSA Pharma	$0.20	$0.20	$0.18 ▼ $1.94	$9.52M	1.57	3.75 million shs	N/A
PYRGF PyroGenesis Canada	$0.14 -5.2%	$0.14	$0.12 ▼ $0.53	$32.46M	0.27	57,661 shs	46,123 shs

10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXS Ayala Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+1,659.62%
CRVO CervoMed	0.00%	-5.45%	-5.08%	-42.69%	-68.81%
EPIX ESSA Pharma	0.00%	0.00%	0.00%	0.00%	-0.74%
PYRGF PyroGenesis Canada	0.00%	+1.06%	-2.78%	-12.45%	-29.98%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXS Ayala Pharmaceuticals	$0.60	$0.60	$0.00 ▼ $0.80	$35.79M	1.75	15,632 shs	N/A
CRVO CervoMed	$2.43 -4.7%	$2.70	$2.13 ▼ $10.00	$36.74M	-0.64	166,180 shs	179,670 shs
EPIX ESSA Pharma	$0.20	$0.20	$0.18 ▼ $1.94	$9.52M	1.57	3.75 million shs	N/A
PYRGF PyroGenesis Canada	$0.14 -5.2%	$0.14	$0.12 ▼ $0.53	$32.46M	0.27	57,661 shs	46,123 shs

10 Best Stocks to Own - Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXS Ayala Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+1,659.62%
CRVO CervoMed	0.00%	-5.45%	-5.08%	-42.69%	-68.81%
EPIX ESSA Pharma	0.00%	0.00%	0.00%	0.00%	-0.74%
PYRGF PyroGenesis Canada	0.00%	+1.06%	-2.78%	-12.45%	-29.98%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADXS Ayala Pharmaceuticals	0.00	N/A	N/A	N/A
CRVO CervoMed	2.71	Moderate Buy	$21.00	764.20% Upside
EPIX ESSA Pharma	1.00	Sell	N/A	N/A
PYRGF PyroGenesis Canada	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest EPIX, CRVO, ADXS, and PYRGF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2026	CRVO CervoMed	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/20/2026	CRVO CervoMed	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$7.00
8/13/2026	CRVO CervoMed	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/12/2026	CRVO CervoMed	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/3/2026	CRVO CervoMed	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/31/2026	CRVO CervoMed	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	CRVO CervoMed	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	CRVO CervoMed	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/9/2026	CRVO CervoMed	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADXS Ayala Pharmaceuticals	$3.24M	11.05	N/A	N/A	($2.06) per share	-0.29
CRVO CervoMed	$4.01M	9.16	N/A	N/A	$1.97 per share	1.23
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	$2.81 per share	N/A
PYRGF PyroGenesis Canada	$9.14M	3.55	N/A	N/A	($0.01) per share	-14.34

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADXS Ayala Pharmaceuticals	-$48.07M	-$5.02	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CRVO CervoMed	-$26.97M	-$3.22	N/A	N/A	N/A	-672.80%	-156.02%	-128.34%	11/12/2026 (Estimated)
EPIX ESSA Pharma	-$28.54M	-$0.56	N/A	N/A	N/A	N/A	-21.71%	-21.22%	N/A
PYRGF PyroGenesis Canada	-$21.12M	-$0.04	N/A	N/A	N/A	-115.14%	N/A	-60.81%	N/A

Latest EPIX, CRVO, ADXS, and PYRGF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/7/2026	Q2 2026	CRVO CervoMed	-$0.8640	-$0.64	+$0.2240	-$0.64	$0.05 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADXS Ayala Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CRVO CervoMed	N/A	N/A	N/A	N/A	N/A
EPIX ESSA Pharma	$1.69	839.96%	N/A	N/A	N/A
PYRGF PyroGenesis Canada	N/A	N/A	N/A	N/A	N/A

Latest EPIX, CRVO, ADXS, and PYRGF Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
1/1/2100	EPIX ESSA Pharma	--	$1.69		8/25/2025	8/19/2025	8/22/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADXS Ayala Pharmaceuticals	N/A	N/A	N/A
CRVO CervoMed	N/A	8.57	8.57
EPIX ESSA Pharma	N/A	69.06	69.06
PYRGF PyroGenesis Canada	N/A	0.60	0.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADXS Ayala Pharmaceuticals	7.18%
CRVO CervoMed	25.15%
EPIX ESSA Pharma	75.12%
PYRGF PyroGenesis Canada	0.03%

Insider Ownership

Company	Insider Ownership
ADXS Ayala Pharmaceuticals	0.63%
CRVO CervoMed	35.80%
EPIX ESSA Pharma	15.50%
PYRGF PyroGenesis Canada	47.68%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADXS Ayala Pharmaceuticals	20	59.31 million	42.36 million	Not Optionable
CRVO CervoMed	15	15.12 million	9.71 million	Not Optionable
EPIX ESSA Pharma	50	47.31 million	39.98 million	Optionable
PYRGF PyroGenesis Canada	90	226.36 million	96.34 million	No Data

EPIX, CRVO, ADXS, and PYRGF Headlines

Recent News About These Companies

PyroGenesis Signs First Contract Toward New Titanium Powder Supply Agreement with U.S. Materials Distributor

September 15, 2026 | globenewswire.com

PyroGenesis Comments on Recently Announced Tariffs

September 14, 2026 | globenewswire.com

PyroGenesis Announces Second Titanium Powder Contract with Metal Additive OEM Client

August 31, 2026 | globenewswire.com

PyroGenesis Announces Second Titanium Powder Contract with DoD and NASA-Supported U.S. Applied Research Facility Client

August 26, 2026 | globenewswire.com

PyroGenesis Announces Titanium Powder Contract with Metal Additive OEM

August 24, 2026 | globenewswire.com

PyroGenesis Announces Titanium Powder Contract with a DoD and NASA-Supported U.S. Applied Research Facility

August 20, 2026 | globenewswire.com

PyroGenesis Announces $1.4 Million Contract to Supply Two Plasma Torches to European Mining, Metallurgy & Materials Entity

August 19, 2026 | globenewswire.com

PyroGenesis Provides Corporate Update on Fumed Silica Business Line

August 17, 2026 | globenewswire.com

PyroGenesis Schedules 2026 Second Quarter Financial Results and Business Update Conference Call

July 31, 2026 | globenewswire.com

PyroGenesis Reports Voting Results From 2026 Meeting of Shareholders

June 23, 2026 | globenewswire.com

PyroGenesis Delivers New Technology to Convert Contaminated Biomass to Syngas

June 17, 2026 | globenewswire.com

P. Peter Pascali Updates Early Warning Report

June 8, 2026 | globenewswire.com

PyroGenesis Announces Closing of $2 Million Private Placement

June 4, 2026 | globenewswire.com

PyroGenesis Announces Closing of $6.26 Million in Financings

June 3, 2026 | globenewswire.com

PyroGenesis Announces Upsize of Bought Deal LIFE Offering to $3.7 Million

May 20, 2026 | globenewswire.com

PyroGenesis Announces $3.0 Million Bought Deal LIFE Offering and Concurrent CEO Private Placement of up to $2.0 Million

May 19, 2026 | newsfilecorp.comN

PyroGenesis Announces a Binding Signed Contract to Acquire its Turcot Manufacturing Facility

May 14, 2026 | globenewswire.com

PyroGenesis Announces First Quarter 2026 Results: Revenue of $4.9 Million, Up 63% ...

May 7, 2026 | caledonianrecord.comC

PyroGenesis Announces First Quarter 2026 Results: Revenue of $4.9 Million, Up 63% Year-Over-Year for Best Quarter Since 2022

May 7, 2026 | globenewswire.com

PyroGenesis Schedules 2026 First Quarter Financial Results and Business Update Conference Call

May 1, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPIX, CRVO, ADXS, and PYRGF Company Descriptions

Ayala Pharmaceuticals NASDAQ:ADXS

$0.60 0.00 (0.00%)

As of 09/18/2026

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

CervoMed NASDAQ:CRVO

$2.43 -0.12 (-4.71%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$2.48 +0.05 (+2.14%)

As of 09/18/2026 07:51 PM Eastern

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

ESSA Pharma NASDAQ:EPIX

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

PyroGenesis Canada NASDAQ:PYRGF

$0.14 -0.01 (-5.16%)

As of 09/18/2026 03:14 PM Eastern

PyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EPIX, CRVO, ADXS, and PYRGF Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EPIX, CRVO, ADXS, and PYRGF Earnings

Compare Dividends

Latest EPIX, CRVO, ADXS, and PYRGF Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EPIX, CRVO, ADXS, and PYRGF Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPIX, CRVO, ADXS, and PYRGF Company Descriptions

Ayala Pharmaceuticals NASDAQ:ADXS

CervoMed NASDAQ:CRVO

ESSA Pharma NASDAQ:EPIX

PyroGenesis Canada NASDAQ:PYRGF

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EPIX, CRVO, ADXS, and PYRGF Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EPIX, CRVO, ADXS, and PYRGF Earnings

Compare Dividends

Latest EPIX, CRVO, ADXS, and PYRGF Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EPIX, CRVO, ADXS, and PYRGF Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPIX, CRVO, ADXS, and PYRGF Company Descriptions

Ayala Pharmaceuticals NASDAQ:ADXS

CervoMed NASDAQ:CRVO

ESSA Pharma NASDAQ:EPIX

PyroGenesis Canada NASDAQ:PYRGF

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools